• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PBT
Click for more information
0.00% 0.0¢

PRANA BIOTECHNOLOGY LIMITED - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
PBT Prana Biotechnology EGM and Conference Call Facility27/03/19
PBT Appendix 3B21/03/19
PBT Prana receives A$3.3 million R&D Tax Incentive RefundPRICE SENSITIVE18/03/19
PBT Notice of General Meeting/Proxy Form06/03/19
PBT Form 6-K01/03/19
PBT Half Yearly Report and AccountsPRICE SENSITIVE28/02/19
PBT Appendix 3B & Cleansing notice05/02/19
PBT Appendix 4C - quarterlyPRICE SENSITIVE31/01/19
PBT Orphan Designation for PBT434 for treatment of MSAPRICE SENSITIVE31/01/19
PBT Ceasing to be a substantial holder from MUFG09/01/19
PBT Ceasing to be a substantial holder from MS09/01/19
PBT Becoming a substantial holder from MUFG07/01/19
PBT Becoming a substantial holder from MS07/01/19
PBT Investor presentation - Biotech Showcase07/01/19
PBT Prana Presents at Biotech Showcase07/01/19
PBT Appendix 3B & Section 708A notice07/01/19
PBT Life Bioscience LLC leads strategic investment upto A$44.5MPRICE SENSITIVE28/12/18
PBT Trading HaltPRICE SENSITIVE24/12/18
PBT Form S-805/12/18
PBT Change of Director's Interest Notice - IS16/11/18
PBT Appendix 3B16/11/18
PBT Results of Meeting16/11/18
PBT 2018 AGM Presentation16/11/18
PBT Prana AGM Investor Conference Call12/11/18
PBT Appendix 4C - quarterlyPRICE SENSITIVE30/10/18
PBT Notice of Annual General Meeting/Proxy Form17/10/18
PBT New data show potential for PBT434 to treat MSAPRICE SENSITIVE05/10/18
PBT Annual report 2018 on Form 20-F & XBRL data filed with SEC03/09/18
PBT Form 20-F03/09/18
PBT Preliminary Final ReportPRICE SENSITIVE31/08/18
PBT Annual Report to shareholdersPRICE SENSITIVE31/08/18
PBT Appendix 4G31/08/18
PBT Appendix 4C - quarterlyPRICE SENSITIVE31/07/18
PBT Appendix 3B and 708A Notice13/07/18
PBT Prana to present PBT434 data at International CongressPRICE SENSITIVE09/07/18
PBT First Volunteers Dosed in Phase I Clinical Trial of PBT434PRICE SENSITIVE04/07/18
PBT Investor Presentation (amended)27/06/18
PBT Investor Presentation - Treatment of Neurological Disorders27/06/18
PBT Prana to commence Phase 1 clinical trial of PBT434PRICE SENSITIVE14/06/18
PBT Appendix 4C - quarterlyPRICE SENSITIVE27/04/18
PBT Prana to Present at the B. Riley FBR Symposium in China16/03/18
PBT PBT434 at the 6th International Multiple System Atrophy ConfPRICE SENSITIVE06/03/18
PBT Form 6-K28/02/18
PBT Half Yearly Report and AccountsPRICE SENSITIVE28/02/18
PBT Appendix 4C - quarterlyPRICE SENSITIVE31/01/18
PBT Appendix 3B18/01/18
PBT Dr. David Stamler presenting at Biotech Showcase08/01/18
PBT Investor Presentation - Treatment of Neurological Disorders08/01/18
PBT Change of Director's Interest Notice22/12/17
PBT Change of Director's Interest Notice22/12/17
PBT Change of Director's Interest Notice22/12/17
PBT Change of Director's Interest Notice22/12/17
PBT Change of Director's Interest Notice22/12/17
PBT Appendix 3B19/12/17
PBT Prana receives $3 million R&D Tax Incentive RefundPRICE SENSITIVE19/12/17
PBT 2017 AGM Results of Meeting17/11/17
PBT AGM 2017 Presentation17/11/17
PBT Prana AGM Investor Conference Call10/11/17
PBT Form 6-K09/11/17
PBT Prospectus SupplementPRICE SENSITIVE09/11/17
PBT Appendix 4C - quarterlyPRICE SENSITIVE30/10/17
PBT Notice of Meeting/ Proxy FormPRICE SENSITIVE13/10/17
PBT Form F-3PRICE SENSITIVE11/10/17
PBT Change of Address25/09/17
PBT Annual Report filed on Form 20-F with SEC06/09/17
PBT Form 20-F01/09/17
PBT Appendix 4G31/08/17
PBT Appendix 4E and Annual ReportPRICE SENSITIVE31/08/17
PBT Appendix 4C - quarterlyPRICE SENSITIVE27/07/17
PBT Prana commences research collaboration with TakedaPRICE SENSITIVE18/07/17
PBT PBT434 Lowers Alpha-Synuclein and Prevents NeurodegenerationPRICE SENSITIVE03/07/17
PBT Change of address26/06/17
PBT Appendix 3B07/06/17
PBT David Stamler appointed as CMO to lead Clinical Development05/06/17
PBT Appendix 4C - quarterlyPRICE SENSITIVE27/04/17
PBT PBT434 presented at 13th International AD/PD ConferencePRICE SENSITIVE30/03/17
PBT Form 6-K24/02/17
PBT Half Year AccountsPRICE SENSITIVE24/02/17
PBT Appendix 4C - quarterlyPRICE SENSITIVE30/01/17
PBT Response to ASX Price QueryPRICE SENSITIVE09/01/17
PBT Business UpdatePRICE SENSITIVE23/12/16
PBT Results of Meeting17/11/16
PBT Prana AGM Investor Webcast Details14/11/16
PBT Prana provides regulatory update for PBT2-PBT.AX PRICE SENSITIVE03/11/16
PBT Prana provides regulatory update for PBT2PRICE SENSITIVE03/11/16
PBT Prana announces $4.8 million R&D refund-PBT.AX PRICE SENSITIVE31/10/16
PBT Appendix 4C - quarterly-PBT.AX PRICE SENSITIVE31/10/16
PBT New Reach2HD data presented at American Neurological Assoc.-PBT.AX PRICE SENSITIVE18/10/16
PBT Notice of Annual General Meeting/Proxy Form-PBT.AX 14/10/16
PBT Prospectus Supplement-PBT.AX 14/10/16
PBT Form 6-K-PBT.AX 14/10/16
PBT Annual Report filed on Form 20-F with SEC-PBT.AX 05/10/16
PBT Form 20F-PBT.AX 05/10/16
PBT Appendix 4G-PBT.AX 30/09/16
PBT Annual Report to shareholders-PBT.AX 30/09/16
PBT Preliminary Final Report-PBT.AX PRICE SENSITIVE28/08/16
PBT Preliminary Final Report-PBT.AX PRICE SENSITIVE26/08/16
PBT Response to ASX Price Query-PBT.AX PRICE SENSITIVE10/08/16
PBT Prana Alzheimer's disease data at world leading conference-PBT.AX 27/07/16
PBT Appendix 4C - quarterly-PBT.AX PRICE SENSITIVE27/07/16
PBT Prana Biotechnology EGM and Conference Call Facility
27/03/19
PBT Appendix 3B
21/03/19
PBT Prana receives A$3.3 million R&D Tax Incentive Refund
18/03/19PRICE SENSITIVE
PBT Notice of General Meeting/Proxy Form
06/03/19
PBT Form 6-K
01/03/19
PBT Half Yearly Report and Accounts
28/02/19PRICE SENSITIVE
PBT Appendix 3B & Cleansing notice
05/02/19
PBT Appendix 4C - quarterly
31/01/19PRICE SENSITIVE
PBT Orphan Designation for PBT434 for treatment of MSA
31/01/19PRICE SENSITIVE
PBT Ceasing to be a substantial holder from MUFG
09/01/19
PBT Ceasing to be a substantial holder from MS
09/01/19
PBT Becoming a substantial holder from MUFG
07/01/19
PBT Becoming a substantial holder from MS
07/01/19
PBT Investor presentation - Biotech Showcase
07/01/19
PBT Prana Presents at Biotech Showcase
07/01/19
PBT Appendix 3B & Section 708A notice
07/01/19
PBT Life Bioscience LLC leads strategic investment upto A$44.5M
28/12/18PRICE SENSITIVE
PBT Trading Halt
24/12/18PRICE SENSITIVE
PBT Form S-8
05/12/18
PBT Change of Director's Interest Notice - IS
16/11/18
PBT Appendix 3B
16/11/18
PBT Results of Meeting
16/11/18
PBT 2018 AGM Presentation
16/11/18
PBT Prana AGM Investor Conference Call
12/11/18
PBT Appendix 4C - quarterly
30/10/18PRICE SENSITIVE
PBT Notice of Annual General Meeting/Proxy Form
17/10/18
PBT New data show potential for PBT434 to treat MSA
05/10/18PRICE SENSITIVE
PBT Annual report 2018 on Form 20-F & XBRL data filed with SEC
03/09/18
PBT Form 20-F
03/09/18
PBT Preliminary Final Report
31/08/18PRICE SENSITIVE
PBT Annual Report to shareholders
31/08/18PRICE SENSITIVE
PBT Appendix 4G
31/08/18
PBT Appendix 4C - quarterly
31/07/18PRICE SENSITIVE
PBT Appendix 3B and 708A Notice
13/07/18
PBT Prana to present PBT434 data at International Congress
09/07/18PRICE SENSITIVE
PBT First Volunteers Dosed in Phase I Clinical Trial of PBT434
04/07/18PRICE SENSITIVE
PBT Investor Presentation (amended)
27/06/18
PBT Investor Presentation - Treatment of Neurological Disorders
27/06/18
PBT Prana to commence Phase 1 clinical trial of PBT434
14/06/18PRICE SENSITIVE
PBT Appendix 4C - quarterly
27/04/18PRICE SENSITIVE
PBT Prana to Present at the B. Riley FBR Symposium in China
16/03/18
PBT PBT434 at the 6th International Multiple System Atrophy Conf
06/03/18PRICE SENSITIVE
PBT Form 6-K
28/02/18
PBT Half Yearly Report and Accounts
28/02/18PRICE SENSITIVE
PBT Appendix 4C - quarterly
31/01/18PRICE SENSITIVE
PBT Appendix 3B
18/01/18
PBT Dr. David Stamler presenting at Biotech Showcase
08/01/18
PBT Investor Presentation - Treatment of Neurological Disorders
08/01/18
PBT Change of Director's Interest Notice
22/12/17
PBT Change of Director's Interest Notice
22/12/17
PBT Change of Director's Interest Notice
22/12/17
PBT Change of Director's Interest Notice
22/12/17
PBT Change of Director's Interest Notice
22/12/17
PBT Appendix 3B
19/12/17
PBT Prana receives $3 million R&D Tax Incentive Refund
19/12/17PRICE SENSITIVE
PBT 2017 AGM Results of Meeting
17/11/17
PBT AGM 2017 Presentation
17/11/17
PBT Prana AGM Investor Conference Call
10/11/17
PBT Form 6-K
09/11/17
PBT Prospectus Supplement
09/11/17PRICE SENSITIVE
PBT Appendix 4C - quarterly
30/10/17PRICE SENSITIVE
PBT Notice of Meeting/ Proxy Form
13/10/17PRICE SENSITIVE
PBT Form F-3
11/10/17PRICE SENSITIVE
PBT Change of Address
25/09/17
PBT Annual Report filed on Form 20-F with SEC
06/09/17
PBT Form 20-F
01/09/17
PBT Appendix 4G
31/08/17
PBT Appendix 4E and Annual Report
31/08/17PRICE SENSITIVE
PBT Appendix 4C - quarterly
27/07/17PRICE SENSITIVE
PBT Prana commences research collaboration with Takeda
18/07/17PRICE SENSITIVE
PBT PBT434 Lowers Alpha-Synuclein and Prevents Neurodegeneration
03/07/17PRICE SENSITIVE
PBT Change of address
26/06/17
PBT Appendix 3B
07/06/17
PBT David Stamler appointed as CMO to lead Clinical Development
05/06/17
PBT Appendix 4C - quarterly
27/04/17PRICE SENSITIVE
PBT PBT434 presented at 13th International AD/PD Conference
30/03/17PRICE SENSITIVE
PBT Form 6-K
24/02/17
PBT Half Year Accounts
24/02/17PRICE SENSITIVE
PBT Appendix 4C - quarterly
30/01/17PRICE SENSITIVE
PBT Response to ASX Price Query
09/01/17PRICE SENSITIVE
PBT Business Update
23/12/16PRICE SENSITIVE
PBT Results of Meeting
17/11/16
PBT Prana AGM Investor Webcast Details
14/11/16
PBT Prana provides regulatory update for PBT2-PBT.AX
03/11/16PRICE SENSITIVE
PBT Prana provides regulatory update for PBT2
03/11/16PRICE SENSITIVE
PBT Prana announces $4.8 million R&D refund-PBT.AX
31/10/16PRICE SENSITIVE
PBT Appendix 4C - quarterly-PBT.AX
31/10/16PRICE SENSITIVE
PBT New Reach2HD data presented at American Neurological Assoc.-PBT.AX
18/10/16PRICE SENSITIVE
PBT Notice of Annual General Meeting/Proxy Form-PBT.AX
14/10/16
PBT Prospectus Supplement-PBT.AX
14/10/16
PBT Form 6-K-PBT.AX
14/10/16
PBT Annual Report filed on Form 20-F with SEC-PBT.AX
05/10/16
PBT Form 20F-PBT.AX
05/10/16
PBT Appendix 4G-PBT.AX
30/09/16
PBT Annual Report to shareholders-PBT.AX
30/09/16
PBT Preliminary Final Report-PBT.AX
28/08/16PRICE SENSITIVE
PBT Preliminary Final Report-PBT.AX
26/08/16PRICE SENSITIVE
PBT Response to ASX Price Query-PBT.AX
10/08/16PRICE SENSITIVE
PBT Prana Alzheimer's disease data at world leading conference-PBT.AX
27/07/16
PBT Appendix 4C - quarterly-PBT.AX
27/07/16PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 

Top Stories

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

CuFe Ltd (ASX:CUF) has decided not to wait around for Northern Star's Crossroads mine to get up and running, selling its $4M royalty right.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado Blue Star Helium (ASX:BNL) has won approval from Colorado regulators to drill five fresh helium wells at its flagship.
Cyclone signs MOU with Vale for development of Iron Bear play Cyclone Metals Lt has signed a Memorandum of Understanding with Vale S.A to support development of the former's iron ore project in Canada
InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy IRX-211 for treatment of Breakthrough Cancer Pain
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.